An observational study in Obesity, sponsored by Istituto Auxologico Italiano. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2025-08-03.
Sponsored by Istituto Auxologico Italiano · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Obesity by Istituto Auxologico Italiano — 11 open to participants now, 12 under way, none of them phase 3. Obesity · Istituto Auxologico Italiano.
Among the 42 studies in Obesity by Istituto Auxologico Italiano, this one is the 2nd largest by planned enrollment of the 20 observational ones that give a count, is one of 7 that started in 2023, is one of 20 observational ones, reaches primary completion later than 3 of the 11 other live ones, and was the 36th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →11 of the 42 studies in Obesity by Istituto Auxologico Italiano are open now, in 1 country. Recruiting first, the newest first:
Istituto Auxologico Italiano · Sites in Italy
Ages 30–70 · Healthy volunteers
Istituto Auxologico Italiano · Sites in Italy
Ages 65+ · Healthy volunteers
Istituto Auxologico Italiano · Sites in Italy
Ages 18–55 · Women only · Healthy volunteers
Istituto Auxologico Italiano · Sites in Italy
Ages 18–65 · Women only
Istituto Auxologico Italiano · Sites in Italy
Ages 18–75
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,000 is above the median of 115 across 2,159 observational studies indexed under Obesity.
Median enrollment 32 across the 22 interventional studies, 80 across the 20 observational. Of the 30 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.
5 of the studies in Obesity by Istituto Auxologico Italiano that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05759637Istituto Auxologico ItalianoType 2 Diabetes, Obesity and Cortisol Excess | 2026-12-31 |
| NCT07614464Istituto Auxologico ItalianoEffects of Obesity on Physical Abilities and Daily Living Activities in Elderly Adults | 2026-12-31 |
| NCT05781269Istituto Auxologico ItalianoLong Term Effect of Very-low-calories Ketogenic Diet on Weight Control and Cardiovascular Brisk Factors (KETOHEART) | 2026-12-31 |
| NCT05772052Istituto Auxologico ItalianoAbnormal Eating and Taste Perception in Subjects With Obesity | 2026-12-31 |
| NCT07935473Istituto Auxologico ItalianoEffects of "Exercise Snack" in Individuals With Obesity | 2027-02-25 |
Add all 5 to your calendar (.ics) → With an account.
Among the 42 studies in Obesity by Istituto Auxologico Italiano, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Overweight and obesity are increasingly prevalent worldwide. Weight excess increases the risk of in developing the metabolic syndrome, which is composed by a set of cardiometabolic risk factors such as abdominal adiposity, dyslipidemia, high blood pressure and elevated fasting glucose levels. Obesity and the metabolic syndrome are known to be risk factors for the development of chronic kidney disease. It is not clear however, whether they can be considered independent risk factors for impaired renal function and renal damage. Whereas obesity may represent an independent risk factor for renal damage, it is not clear yet if the contemporaneous presence of obesity and metabolic alterations is associated with an additional increase in the risk.
It may be important to understand the relationship between obesity, metabolic syndrome and renal health, as treatment strategies may be different for the two metabolic phenotypes of obesity, i.e., metabolically healthy obese (MHO) and metabolically unhealthy obese (MUO) patients.
The primary objective of this multicentre observational prospective study is to assess the relationship between metabolic phenotype and reduced renal function (glomerular filtration rate \<90 ml/min/1.73m2 or microalbuminuria 30-300 mg/24h) in a population of 1000 patients with overweight or obesity.
The secondary aim is to study the association between diet quality, consumption of ultra-processed foods and indicators of reduced renal function and renal damage.
1000 patients with weight excess or overweight (BMI > 25 kg/m2)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: Diet
Pesonalized diet plan, devoloped according to Guidelines for dietary treatment of obesity, to be followed for a duration of 12 months
Glomerular filtration rate
Change in glomerular filtration after dietary intervention of 12 months
Time frame: At baseline and after 12 months of dietary intervention programme
Microalbuminuria
Change in microalbuminuria after dietary intervention of 12 months
Time frame: At baseline and after 12 months of dietary intervention programme
Glycemia
Change in glycemia after dietary intervention of 12 months
Time frame: At baseline and after 12 months of dietary intervention programme
Body mass index
Change in body mass index after dietary intervention of 12 months
Time frame: At baseline and after 12 months of dietary intervention programme
Started Aug 2023 (actual). Primary completion is estimated for Dec 2025, 28 months after the start.
Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 28 months is below that.
Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Istituto Auxologico Italiano →